<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; dilemma</title>
	<atom:link href="http://www.tapanray.in/tag/dilemma/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma: ‘Digitalization’ Not A Panacea – A Basic Step For Giant Leaps</title>
		<link>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps</link>
		<comments>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/#comments</comments>
		<pubDate>Mon, 07 Oct 2019 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[backbone]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[domains]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[panacea]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformation]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9736</guid>
		<description><![CDATA[The hype of ‘Digitalization’ in the pharma industry, virtually as a panacea, is palpable all around. It gives many a feel, directly or indirectly, that this one-time, resource-intensive, disruptive transformation would reap a rich harvest for a long time. In &#8230; <a href="http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Therapy Price: Commercial Viability And Moral Dilemma</title>
		<link>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gene-therapy-price-commercial-viability-and-moral-dilemma</link>
		<comments>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/#comments</comments>
		<pubDate>Mon, 17 Jun 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercially]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moral]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spinraza]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[viability.]]></category>
		<category><![CDATA[viable]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9586</guid>
		<description><![CDATA[On May 24, 2019, Novartis announced the US-FDA approval of ‘the first and only gene therapy’ – Zolgensma, for a type of Spinal Muscular Atrophy (SMA), a lifesaving treatment for infants of less than 2 years of age. This unique drug halts disease progression &#8230; <a href="http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
